Early levodopa treatment: Does it slow or hasten Parkinson's?

April 01, 2003

HONOLULU, HI -- Levodopa is the most effective treatment for Parkinson's disease, but some laboratory studies have raised concern that it may hasten disease progression. Those fears appear to have been laid to rest by the clinical results of a large double-blind study - the Elldopa Trial by the Parkinson Study Group -- to be presented during the 55th Annual Meeting of the American Academy of Neurology in Honolulu, March 29-April 5. However, contradictory neuroimaging results from the same study may keep the question alive.

Three hundred sixty-one untreated patients with early Parkinson's disease were given either a placebo or one of three doses of levodopa for 40 weeks. Patients were tested before and two weeks after treatment with the Unified Parkinson's Disease Rating Scale (UPDRS), the standard measure of disease-related clinical disability. After the two-week washout, patients who had received levodopa scored better on the UPDRS than those who received placebo, and those receiving the highest dose did best. Other measures showed similar results, including Quality of Life and Activities of Daily Living scores.

According to Stanley Fahn, MD, "The clinical outcomes did not show that levodopa hastened worsening of the disease, but rather that levodopa may have slowed the rate of progression, although the 2-week washout design would not have detected the presence of a more sustained symptomatic benefit rather than a slowing of the disease progression." In addition to being the lead study author, Fahn is the current president of the American Academy of Neurology.

Before-and-after neuroimaging studies, conducted in a subset of patients, indicated a 4 to 7 percent decline in dopamine-producing cells in levodopa-treated patients, versus only a 1 percent decline in placebo-treated patients. "In contrast to the clinical results, the imaging substudy suggests that levodopa caused a more rapid decline in the nigrostriatal nerve terminals," said Fahn of the cells that release dopamine in the brain. "These contradictory findings warrant further investigation into the effect of levodopa on Parkinson's disease, and a pharmacologic effect by levodopa on this type of imaging study needs to be investigated."
-end-
The study was supported by the National Institutes of Health and the Department of Defense.

The American Academy of Neurology, an association of more than 18,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. For more information about the American Academy of Neurology, visit its website at www.aan.com. The 2003 American Academy of Neurology annual meeting - the world's largest international neurology meeting - takes place at the Hawaii Convention Center in Honolulu from March 29 to April 5.

Editor's note: Dr. Fahn will present his research at 2 p.m. on Tues., April 1 in Room 310 of the Hawaii Convention Center.

Please visit or call the AAN Press Room at 808-792-6630 to arrange an interview with Dr. Fahn regarding the study. The AAN Press Room is Room 327 of the Hawaii Convention Center.

All listed times are for Hawaiian-Aleutian Standard Time (HT).

For more information contact:
Kathy Stone, 651-695-2763, kstone@aan.com
March 29-April 5 -- 808-792-6630
Marilee Reu, 651-695-2789, mreu@aan.com

American Academy of Neurology

Related Disease Articles from Brightsurf:

CLCN6 identified as disease gene for a severe form of lysosomal neurodegenerative disease
A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder.

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

Potential link for Alzheimer's disease and common brain disease that mimics its symptoms
A new study by investigators from Brigham and Women's Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer's symptoms.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Tools used to study human disease reveal coral disease risk factors
In a study published in Scientific Reports, a team of international researchers led by University of Hawai'i (UH) at Mānoa postdoctoral fellow Jamie Caldwell used a statistical technique typically employed in human epidemiology to determine the ecological risk factors affecting the prevalence of two coral diseases--growth anomalies, abnormalities like coral tumors, and white syndromes, infectious diseases similar to flesh eating bacteria.

Disease-aggravating mutation found in a mouse model of neonatal mitochondrial disease
The new mitochondrial DNA (mtDNA) variant drastically speeds up the disease progression in a mouse model of GRACILE syndrome.

Human longevity largest study of its kind shows early detection of disease & disease risks
Human Longevity, Inc. (HLI) announced the publication of a ground-breaking study in the journal Proceedings of the National Academy of Sciences (PNAS).

30-year study identifies need of disease-modifying therapies for maple syrup urine disease
A new study analyzes 30 years of patient data and details the clinical course of 184 individuals with genetically diverse forms of Maple Syrup Urine Disease (MSUD), which is among the most volatile and dangerous inherited metabolic disorders.

Long-dormant disease becomes most dominant foliar disease in New York onion crops
Until recently, Stemphylium leaf blight has been considered a minor foliar disease as it has not done much damage in New York since the early 1990s.

Read More: Disease News and Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.